UK on track to eliminate hepatitis C five years ahead of target

28 December 2022
nhs_big

Britain’s national healthcare provider, NHS England, says the UK is on track to eliminate hepatitis C by 2025, following a “concerted effort to find people at risk.”

Eliminating the virus in that timeframe would represent a five-year improvement on the global target set by the World Health Organization to achieve the milestone.

People with hepatitis C have benefitted from a dramatic improvement in treatment outcomes in recent years, thanks to the development of a curative antiviral by Gilead Sciences (Nasdaq: GILD).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical